Inovio Pharmaceuticals (INO) Share-based Compensation (2010 - 2026)

Inovio Pharmaceuticals has disclosed Share-based Compensation across 17 years of filings, most recently posting $753000.0 for Q2 2026.

• In Q2 2026, Share-based Compensation fell 8.06% year-over-year to $753000.0; the TTM figure through Jun 2026 stood at $3.0 million (down 37.51% YoY), while the FY2025 annual figure was $3.8 million, down 43.05% from the prior year.
• Share-based Compensation came in at $753000.0 for Q2 2026 at Inovio Pharmaceuticals, up from $698744.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $14.0 million in Q1 2023 to a low of $698744.0 in Q1 2026.
• Average Share-based Compensation over 5 years is $3.1 million, with a median of $1.5 million recorded in 2024.
• Year-over-year, Share-based Compensation slumped 93.52% in 2022 and jumped 81.56% in 2023.
• Over 5 years, Share-based Compensation stood at $3.3 million in 2022, then sank by 41.97% to $1.9 million in 2023, then plunged by 30.75% to $1.3 million in 2024, then plunged by 41.89% to $764561.0 in 2025, then declined by 1.51% to $753000.0 in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $753000.0 in Q2 2026, $698744.0 in Q1 2026, and $764561.0 in Q4 2025.